Agilent and ASI agree new co-marketing agreement

Agilent Technologies has announced a new co-marketing agreement with Applied Spectral Imaging (ASI).

The companies will jointly market ASI's advanced GenASIs imaging platforms and Agilent's fluorescence in situ hybridisation (FISH) products and solutions, including its Dako Omnis instrument for automated FISH sample processing.

This will ensure pathology labs are able to source the components they require for a fully automated end-to-end FISH workflow in as seamless a manner as possible.

ASI is recognised as a global leader in the development of imaging solutions, supporting fluorescent, brightfield and spectral image-acquisition, for karyotyping, FISH and various pathology tests.

Herman Verrelst, vice-president and general manager of Agilent's genomics solutions and clinical applications divisions, said: "We anticipate that Agilent's broad portfolio of FISH reagents and instruments, and ASI's industry-leading computer-aided imaging solutions, will address such critical customer needs and enable laboratories to have a standardised, efficient and high-quality FISH workflow."

Agilent exceeded its financial guidance during the first quarter of the 2016 business year, thanks to the strong performance of its CrossLab and diagnostics/genomics divisions.